A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
Clinical trial NCT06087419 · UNKNOWN
Trial details
- NCT number
- NCT06087419
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-30
- Primary completion
- 2024-12-30
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.